XOMA Royalty (LSE:0M26) - Stock Price, News & Analysis

0M26 Stock Overview

Operates as a biotech royalty aggregator in the United States and the Asia Pacific. More details

0M26 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 77.96% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

XOMA Royalty Corporation Competitors

Oxford Biomedica

LSE:OXB

UK£447.8m

Bioventix

AIM:BVXP

UK£195.7m

Genus

LSE:GNS

UK£1.1b

OptiBiotix Health

AIM:OPTI

UK£13.0m

Price History & Performance

Summary of all time highs, changes and price drops for XOMA Royalty
Historical stock prices
Current Share Price	US$31.00
52 Week High	US$32.87
52 Week Low	US$15.95
Beta	0.90
11 Month Change	8.85%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	19.88%
5 Year Change	n/a
Change since IPO	-7.16%

Recent updates

Shareholder Returns

	0M26	GB Biotechs	GB Market
7D	0.6%	1.5%	2.2%
1Y	n/a	-17.9%	8.8%

Return vs Industry: Insufficient data to determine how 0M26 performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0M26 performed against the UK Market.

Price Volatility

Is 0M26's price volatile compared to industry and market?
0M26 volatility
0M26 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0M26's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0M26's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	13	Owen Hughes	xoma.com

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

XOMA Royalty Corporation Fundamentals Summary

How do XOMA Royalty's earnings and revenue compare to its market cap?
0M26 fundamental statistics
Market cap	US$365.38m
Earnings (TTM)	-US$35.43m
Revenue (TTM)	US$21.61m

16.9x

P/S Ratio

-10.3x

P/E Ratio

Is 0M26 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0M26 income statement (TTM)
Revenue	US$21.61m
Cost of Revenue	US$2.04m
Gross Profit	US$19.57m
Other Expenses	US$55.00m
Earnings	-US$35.43m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-3.01
Gross Margin	90.58%
Net Profit Margin	-164.00%
Debt/Equity Ratio	139.0%

How did 0M26 perform over the long term?

See historical performance and comparison

0M26 Stock Overview

Rewards

Risk Analysis

XOMA Royalty Corporation Competitors

LSE:OXB

UK£447.8m

AIM:BVXP

UK£195.7m

LSE:GNS

UK£1.1b

AIM:OPTI

UK£13.0m

Price History & Performance

Recent News & Updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$1.47 loss per share (vs US$0.60 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.37 (vs US$0.59 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.86 loss per share (vs US$0.98 loss in 1Q 2023)

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$1.47 loss per share (vs US$0.60 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.37 (vs US$0.59 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.86 loss per share (vs US$0.98 loss in 1Q 2023)

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Full year 2023 earnings released: US$3.56 loss per share (vs US$1.98 loss in FY 2022)

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2022)

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings released: US$1.50 loss per share (vs US$0.69 profit in FY 2021)

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.51 loss in 3Q 2021)

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.31 loss in 2Q 2021)

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

CEO & Director recently sold US$303k worth of stock

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

Full year 2020 earnings released: EPS US$0.82 (vs US$0.23 loss in FY 2019)

Revenue beats expectations

Shareholder Returns

Price Volatility

About the Company

XOMA Royalty Corporation Fundamentals Summary

16.9x

-10.3x

Earnings & Revenue